Skip to main content
Home

GBL

Main navigation

  • About GBL
      About GBL
    • Our purpose
    • Shareholding
    • Governance
      • Board of Directors
      • Board Committees
      • Corporate governance
    • ESG
      • Sustainability
      • GBL ACT
    • Risk Management
    • Business model
  • Portfolio
      Portfolio
    • Listed assets
      • 55% of GBL’s portfolio
      • adidas
      • Concentrix
      • Imerys
      • Ontex
      • Pernod Ricard
      • SGS
      • Umicore
    • Direct private assets
      • 24% of GBL’s portfolio
      • Affidea
      • Canyon
      • Parques Reunidos
      • Sanoptis
      • Voodoo
    • Indirect private assets
      • 20% of GBL’s portfolio
      • Funds
      • Co-investments
    • Third-party asset management
      • 1% of GBL’s portfolio
  • Investors
      Investors
    • GBL Share
      • Stock price & key share information
      • Dividend
      • Total Shareholder Return
      • Capital and form of shares
      • Voting rights and denominator
      • Transactions on GBL shares
    • Key Financial Information
      • Net asset value
      • Net financial position
      • Credit rating
      • Consolidated net result & Cash earnings
      • Glossary
    • Analysts
    • General Meeting
    • Financial Calendar
    • Strategic Update
    • Prospectus
  • Culture & Careers
  • Media Center
      Media Center
    • Press releases
    • Annual & Half-year reports
    • IR Presentations
    • Analyst Presentations
    • Voting rights and denominator
    • Transactions on GBL shares
    • Subscription Form
72.00 €
Stock price
06/13/202517:35
Funds

Sagard

ProalphaPrevious
svtNext
Sagard
Established in 2002, Sagard invests in companies valued at more than EUR 100 million that are leaders in their markets, primarily in French-speaking European countries
€ 285 M NAV
€ 426 M Invested capital - total
€ 599 M Distributions - total
€ 24 M Unfunded commitments - total
10% % of GBL Capital's portfolio
Business area
Private equity
Registered office
Paris, France
Year of initial investment
2002

All figures are as of December 31, 2024, unless otherwise stated

Read more
Scroll to content
ProalphaPrevious
svtNext

Main navigation

  • About GBL
      About GBL
    • Our purpose
    • Shareholding
    • Governance
      • Board of Directors
      • Board Committees
      • Corporate governance
    • ESG
      • Sustainability
      • GBL ACT
    • Risk Management
    • Business model
  • Portfolio
      Portfolio
    • Listed assets
      • 55% of GBL’s portfolio
      • adidas
      • Concentrix
      • Imerys
      • Ontex
      • Pernod Ricard
      • SGS
      • Umicore
    • Direct private assets
      • 24% of GBL’s portfolio
      • Affidea
      • Canyon
      • Parques Reunidos
      • Sanoptis
      • Voodoo
    • Indirect private assets
      • 20% of GBL’s portfolio
      • Funds
      • Co-investments
    • Third-party asset management
      • 1% of GBL’s portfolio
  • Investors
      Investors
    • GBL Share
      • Stock price & key share information
      • Dividend
      • Total Shareholder Return
      • Capital and form of shares
      • Voting rights and denominator
      • Transactions on GBL shares
    • Key Financial Information
      • Net asset value
      • Net financial position
      • Credit rating
      • Consolidated net result & Cash earnings
      • Glossary
    • Analysts
    • General Meeting
    • Financial Calendar
    • Strategic Update
    • Prospectus
  • Culture & Careers
  • Media Center
      Media Center
    • Press releases
    • Annual & Half-year reports
    • IR Presentations
    • Analyst Presentations
    • Voting rights and denominator
    • Transactions on GBL shares
    • Subscription Form

Groupe Bruxelles Lambert (GBL)

Avenue Marnix 24
B-1000 Brussels

Contact

Reception
+32 2 289 17 86
cdumasy@gbl.com

Investor Relations

Alison Donohoe
+32 2 289 17 64
adonohoe@gbl.com
 

© 2025 GBL, all rights reserved

Footer Menu

  • Legal Notice
  • General Privacy Policy
  • Cookie policy

Made by Globule Bleu